Implantable neurostimulation devices market seen reaching $10.01 billion by 2030

The Business Research Company says the implantable neurostimulation devices market is set to grow from $5.62 billion in 2025 to $10.02 billion by 2030, driven by rising neurological disorders and demand for non-drug therapies. North America led the market in 2025, while Asia-Pacific is expected to be the fastest-growing region.

Why it matters: - Implantable neurostimulation devices are becoming a bigger part of treatment for neurological conditions that do not respond well to medication. - The market’s growth reflects rising demand for non-drug therapies, outpatient neurological care and precision neuromodulation. - The forecast points to broader adoption of implantable stimulation as an alternative for patients with chronic symptoms.

What happened: - The Business Research Company released a new market report on implantable neurostimulation devices on August 11, 2026. - The report projects the market will rise from $5.62 billion in 2025 to $6.27 billion in 2026. - The report forecasts the market will reach $10.02 billion by 2030. - The report links the outlook to a 11.7% CAGR from 2025 to 2026 and a 12.4% CAGR through 2030. - Download a free sample of the report. - View the full market report.

The details: - Implantable neurostimulation devices deliver electrical impulses to targeted areas of the nervous system. - The devices are surgically placed inside the body to modulate nerve activity. - The technology is used to manage neurological and psychological disorders. - The report says the devices are especially useful for patients whose symptoms do not respond adequately to medication. - Historical growth has been supported by higher rates of neurological disorders, broader adoption of pain management therapies, wider clinical acceptance of neuromodulation and better availability of implantable electronic systems. - Expected growth drivers include rising demand for non-drug therapies, precision neuromodulation, expansion of outpatient neurological care, more investment in brain-machine interface research and improvements in stimulation algorithms. - Expected trends include more use of advanced neurostimulation therapies, rechargeable devices, personalized treatments, multi-indication systems and longer-lasting outcomes. - In 2024, the Alzheimer's Association reported about 6.9 million Americans age 65 and older were living with Alzheimer’s disease. - The Alzheimer's Association said 73% of those patients were 75 years or older. - The association projects that number will rise to 12.7 million by 2050.

Between the lines: - The market outlook suggests neurostimulation is moving from a niche intervention toward a more mainstream treatment category. - The emphasis on rechargeable, personalized and multi-indication devices points to a push for products that can serve more patients with fewer procedures. - North America’s leading position suggests the region’s healthcare infrastructure and medtech spending remain key advantages. - Asia-Pacific’s expected growth signals faster adoption where healthcare investment and awareness are still expanding.

What's next: - The market is expected to keep accelerating through 2030 as neurological disease rates climb and device capabilities improve. - The report highlights future opportunities in outpatient care models and brain-machine interface research. - The company says its 2026 reports now include market attractiveness scoring, TAM analysis, company scoring matrix graphics, forecasting dashboards, hotspot infographics and updated trend analysis. - The report covers North America, Asia-Pacific, South East Asia, Western Europe, Eastern Europe, South America, the Middle East and Africa.

The bottom line: - Implantable neurostimulation is emerging as a fast-growing medtech market, with demand rising as more patients and providers look beyond drug-based treatments.